222 related articles for article (PubMed ID: 37294331)
21. An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer.
Powles T; Carroll D; Chowdhury S; Gravis G; Joly F; Carles J; Fléchon A; Maroto P; Petrylak D; Rolland F; Cook N; Balar AV; Sridhar SS; Galsky MD; Grivas P; Ravaud A; Jones R; Cosaert J; Hodgson D; Kozarewa I; Mather R; McEwen R; Mercier F; Landers D
Nat Med; 2021 May; 27(5):793-801. PubMed ID: 33941921
[TBL] [Abstract][Full Text] [Related]
22. [Molecular tumor board-renal cell carcinoma].
Grünwald V; Doehn C; Goebell PJ
Urologe A; 2019 Jul; 58(7):768-773. PubMed ID: 31175376
[TBL] [Abstract][Full Text] [Related]
23. The rapidly evolving treatment landscape of advanced prostate, bladder, and renal cell carcinomas.
Hahn AW; Agarwal N
Cancer Treat Res Commun; 2020; 24():100190. PubMed ID: 32679555
[No Abstract] [Full Text] [Related]
24. Induction of apoptosis through inactivation of ROS-dependent PI3K/Akt signaling pathway by platycodin D in human bladder urothelial carcinoma cells.
Park C; Cha HJ; Lee H; Jeong JW; Han M; Song KS; Kim GY; Chang YC; Leem SH; Hyun JW; Kim HS; Hong SH; Choi YH
Gen Physiol Biophys; 2022 Jul; 41(4):263-274. PubMed ID: 35938960
[TBL] [Abstract][Full Text] [Related]
25. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics.
Zhong H; Chiles K; Feldser D; Laughner E; Hanrahan C; Georgescu MM; Simons JW; Semenza GL
Cancer Res; 2000 Mar; 60(6):1541-5. PubMed ID: 10749120
[TBL] [Abstract][Full Text] [Related]
26. Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration-resistant prostate cancer.
Park H; Kim Y; Sul JW; Jeong IG; Yi HJ; Ahn JB; Kang JS; Yun J; Hwang JJ; Kim CS
Prostate; 2015 Nov; 75(15):1747-59. PubMed ID: 26250606
[TBL] [Abstract][Full Text] [Related]
27. MET inhibition enhances PARP inhibitor efficacy in castration-resistant prostate cancer by suppressing the ATM/ATR and PI3K/AKT pathways.
Zhou S; Dai Z; Wang L; Gao X; Yang L; Wang Z; Wang Q; Liu Z
J Cell Mol Med; 2021 Dec; 25(24):11157-11169. PubMed ID: 34761497
[TBL] [Abstract][Full Text] [Related]
28. Novel Tyrosine Kinase Targets in Urothelial Carcinoma.
Torres-Jiménez J; Albarrán-Fernández V; Pozas J; Román-Gil MS; Esteban-Villarrubia J; Carrato A; Rosero A; Grande E; Alonso-Gordoa T; Molina-Cerrillo J
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33451055
[TBL] [Abstract][Full Text] [Related]
29. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway.
Blancher C; Moore JW; Robertson N; Harris AL
Cancer Res; 2001 Oct; 61(19):7349-55. PubMed ID: 11585776
[TBL] [Abstract][Full Text] [Related]
30. Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma.
Seront E; Rottey S; Filleul B; Glorieux P; Goeminne JC; Verschaeve V; Vandenbulcke JM; Sautois B; Boegner P; Gillain A; van Maanen A; Machiels JP
BJU Int; 2016 Sep; 118(3):408-15. PubMed ID: 26779597
[TBL] [Abstract][Full Text] [Related]
31. Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.
Wang D; Li C; Zhang Y; Wang M; Jiang N; Xiang L; Li T; Roberts TM; Zhao JJ; Cheng H; Liu P
Gynecol Oncol; 2016 Sep; 142(3):548-56. PubMed ID: 27426307
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells.
Li H; Jin X; Zhang Z; Xing Y; Kong X
Cell Biochem Funct; 2013 Jul; 31(5):427-33. PubMed ID: 23086777
[TBL] [Abstract][Full Text] [Related]
33. Poly(ADP-ribose) polymerase inhibitors in prostate cancer: a cornerstone in precision oncology.
Ziadeh T; Kourie HR
Pharmacogenomics; 2021 Dec; 22(18):1237-1250. PubMed ID: 34729995
[TBL] [Abstract][Full Text] [Related]
34. Emerging strategies to overcome the resistance to current mTOR inhibitors in renal cell carcinoma.
Santoni M; Pantano F; Amantini C; Nabissi M; Conti A; Burattini L; Zoccoli A; Berardi R; Santoni G; Tonini G; Santini D; Cascinu S
Biochim Biophys Acta; 2014 Apr; 1845(2):221-31. PubMed ID: 24480319
[TBL] [Abstract][Full Text] [Related]
35. Molecular therapy in urologic oncology.
Froehner M; Hakenberg OW; Wirth MP
Urol Int; 2007; 79(1):1-7. PubMed ID: 17627159
[TBL] [Abstract][Full Text] [Related]
36. [Systemic immune checkpoint inhibition : A promising treatment for urological tumors?].
Roos FC; Becker C; Stope MB; Tsaur I;
Urologe A; 2018 May; 57(5):583-590. PubMed ID: 29569115
[TBL] [Abstract][Full Text] [Related]
37. Predictive and Prognostic Biomarkers and Tumor Antigens for Targeted Therapy in Urothelial Carcinoma.
Eturi A; Bhasin A; Zarrabi KK; Tester WJ
Molecules; 2024 Apr; 29(8):. PubMed ID: 38675715
[TBL] [Abstract][Full Text] [Related]
38. PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer.
Marquard FE; Jücker M
Biochem Pharmacol; 2020 Feb; 172():113729. PubMed ID: 31785230
[TBL] [Abstract][Full Text] [Related]
39. Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer.
Facchinetti F; Hollebecque A; Braye F; Vasseur D; Pradat Y; Bahleda R; Pobel C; Bigot L; Déas O; Florez Arango JD; Guaitoli G; Mizuta H; Combarel D; Tselikas L; Michiels S; Nikolaev SI; Scoazec JY; Ponce-Aix S; Besse B; Olaussen KA; Loriot Y; Friboulet L
Cancer Discov; 2023 Sep; 13(9):1998-2011. PubMed ID: 37377403
[TBL] [Abstract][Full Text] [Related]
40. mTOR in renal cell cancer: modulator of tumor biology and therapeutic target.
Wysocki PJ
Expert Rev Mol Diagn; 2009 Apr; 9(3):231-41. PubMed ID: 19379082
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
